The IASLC 2025 Hot Topic Meeting: Small Cell Lung Cancer is a biannual international meeting focused on preclinical and clinical advances in small cell lung cancer research. This includes basic research on oncogenesis and biology of disease, preclinical therapeutic research, and highlights of ongoing clinical translation.

The conference provides medical professionals and researchers with a comprehensive view of the latest advancements in understanding and treating this aggressive disease. Sessions covering diverse topics—from pathology and pulmonary neuroendocrine neoplasms to cutting-edge epigenetics and novel therapeutic approaches—offer attendees unique insights into both the biological underpinnings and clinical treatment options. By focusing on immunotherapy, cell surface targeting, and the role of mouse models, we aim to equip lab researchers and medical oncologists with the knowledge they need to innovate and improve patient outcomes. This conference is a rare opportunity to connect with experts, gain exposure to the latest clinical trials, and contribute to a shared mission of advancing care for patients with Small Cell Lung Cancer. 

The meeting is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants and nurses.

Upon completion of this activity, the participants should be able to: 

• Review the latest advancements in understanding and treating small cell lung cancer.
• Examine preclinical and clinical advances in small cell lung cancer research.
• Evaluation the basic research on oncogenesis and biology of disease, preclinical therapeutic research, and highlights of ongoing clinical translation. 
• Provide researchers and medical oncologists with the knowledge needed to innovate and improve patient outcomes.

• Kristy Lastwika, PhD, Fred Hutch Cancer Center
• Benjamin Lok, MD, FRCPC, Princess Margaret Cancer Centre
• Matthew Oser, MD, PhD, Dana-Farber Cancer Institute
• Natasha Rekhtman, MD, PhD, Memorial Sloan Kettering Cancer Center
• Anish Thomas, MBBS, MD, National Cancer Institute

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

For assistance with this activity, please email: education@iaslc.org.